Fast progression in non-small cell lung cancer: Results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

David Gandara, Martin Reck, Denis Moro-Sibilot, Julien Mazieres, Shirish Gadgeel, Stefanie Morris, Andres Cardona, Diana Mendus, Marcus Ballinger, Achim Rittmeyer, Solange Peters

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Fast progression in non-small cell lung cancer: Results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel'. Together they form a unique fingerprint.

Medicine & Life Sciences